Related Experiment Video

Updated: May 6, 2026

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

17.2K

The EuroNet paediatric hodgkin network - modern imaging data management for real time central review in multicentre

L Kurch1, C Mauz-Körholz, S Bertling

  • 1Department of Nuclear Medicine, University Hospital of Leipzig, Germany.

Klinische Padiatrie
|October 30, 2013
PubMed

Insights

The EuroNet Paediatric Hodgkin Data Network facilitates efficient, secure data sharing for children with Hodgkin lymphoma. This network improves multi-center trial quality control and therapy management through centralized image review.

Area of Science:

  • Pediatric Oncology
  • Clinical Trials
  • Medical Imaging

Background:

  • Children and adolescents with Hodgkin lymphoma are treated in Europe-wide EuroNet-PHL trials since 2007.
  • Centralized review of cross-sectional images is crucial for patient stratification, quality control, and efficient therapy management.
  • Time-critical reference evaluations necessitate fast, secure, and accessible data transfer.

Purpose of the Study:

  • To describe the operational model of the EuroNet Paediatric Hodgkin Data Network.
  • To highlight the advantages of centralized image review in multi-center pediatric Hodgkin lymphoma trials.
  • To detail the data protection measures implemented within the network.

Main Methods:

  • Establishment of the EuroNet Paediatric Hodgkin Data Network (2008-2011) funded by the European Union.
  • Implementation of a real-time central review process for cross-sectional imaging.
  • Development and application of a tailored data protection plan.

Main Results:

  • The network ensures immediate and constant access to data for queries and regulatory compliance.
  • Facilitates efficient therapy management through real-time patient stratification.
  • Enhances quality control in multi-center clinical trials by centralizing image review.

Conclusions:

  • The EuroNet Paediatric Hodgkin Data Network provides a robust framework for multi-center pediatric Hodgkin lymphoma trials.
  • Centralized image review is advantageous for quality control and efficient management.
  • Secure and accessible data management is essential for international clinical research.

More Related Videos

Whole-body PET/MRI of Pediatric Patients: The Details That Matter10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

14.8K
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

2.2K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
562
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
982
Imaging Studies I: Kidney, Ureter, and Bladder Studies01:28

Imaging Studies I: Kidney, Ureter, and Bladder Studies

Kidney, Ureter, and Bladder (KUB) StudiesKidney, Ureter, and Bladder (KUB) studies are standard diagnostic imaging procedures used to assess the anatomy of the urinary system. They are commonly utilized for patients experiencing abdominal pain or urinary symptoms. By using a simple X-ray of the abdomen, KUB studies can reveal structural and pathological abnormalities within the kidneys, ureters, and bladder. These studies are particularly valuable in diagnosing kidney stones, urinary...
884
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
863
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
417